The oral administration of forphenicinol increased the survival rate of both normal and immunodepressed mice intraperitoneally or intratracheally infected with clinically isolated strains of Pseudomonasaeruginosa. The therapeutic effect of amikacin on intraperitoneal infection with P. aeruginosa was enhanced by combined use with forphenicinol.
immunodepressed mice intraperitoneally or intratracheally infected with clinically isolated strains of Pseudomonasaeruginosa. The therapeutic effect of amikacin on intraperitoneal infection with P. aeruginosa was enhanced by combined use with forphenicinol.
Forphenicinol did not enhance the bactericidal activity of polymorphonuclear cells (PMN)towards P. aeruginosa in vitro, but enhanced it in vivo. In vitro study indicated that the macrophages taken from mice treated with forphenicinol or the cultured supernatant of these macrophages enhanced the bactericidal activity of PMN.The protective effect of forphenicinol against P. aeruginosa infection was thus suggested to be due to macrophage activation followed by the enhancement of the bactericidal activity of PMN. Forphenicinol, glycine, enhances delayed-type hypersensitivity in both normal and immunodepressed mice and phagocytic activity of peritoneal macrophagesi:>. Although it had neither tumoricidal nor bactericidal activity in vitro, it inhibited the growth of experimental tumors and increased resistance to infection with Pseudomonasaeruginosa in mice2~4).
In this paper, we report on further study of the effect of forphenicinol against P. aeruginosa infection and its mechanisms.
Materials and Methods

Animals
Specific pathogen-free female ICR mice were purchased from Charles River Japan, Inc. (Kanagawa) and maintained in a barrier system. They were 5 weeks old at the start of each experiment. In the case of experiments using immunodepressedmice, mice were injected with cyclophosphamide (Shionogi & Co., Ltd., Osaka) or hydrocortisone (Tokyo Kasei Co., Ltd., Tokyo) prior to infection. Cyclophosphamide was given intraperitoneally 4 days before infection at a dose of 50 to 200 mg/kg. Hydrocortisone was given subcutaneously at a dose of 40 mg/kg once daily for 4 days before infection. APR. 1987 Medicine, Nagasaki University, Nagasaki) and a clinical isolate (code; CPa) obtained from Tokyo Clinical Research Center, were used in some experiments. Their LD50values in intravenous infection were from 3.0x lO6 to 1.0x lO7 cfu/mouse and were smaller than that of P. aeruginosa No. 12 (2.0x 108 cfu/mouse). Each isolate was grown over night on a tryptic soy agar plate (Eiken, Tokyo), thereafter suspended in saline at the desired concentration. Since P. aeruginosa No. 12 tends to lose its virulence after in vitro passage of more than 1 month, the bacteria was renewed from lyophilized sources every month. The number of viable P. aeruginosa cells (cfu) was counted by spreading 0.1 ml of the cell suspension on nutrient agar plates containing 3 % (weight/vol) tryptic soy, 1.7% agar (Difco Laboratories, Detroit, Mich., U.S.A.) and 0.02% cetrimide (Wako Pure Chemicals Ind., Osaka). Cetrimide allowed about 80%of the growth of P. aeruginosa at the concentration of 0.02%, however it inhibited the growth of other bacteria.
Forphenicinol and Amikacin Forphenicinol was synthesized by Banyu Pharmaceutical Co., Ltd., according to the method described by Morishima et al.5) and was given orally at doses of 0.01 to 1.0 mg/kg before or after infection. Amikacin (0.125 or 0.25 mg/mouse, Banyu Pharmaceutical Co., Ltd., Tokyo) was given intramuscularly 1 hour after infection. Infection P. aeruginosa suspension of various concentrations (0.1 ml) was injected intravenously or intraperitoneally on day 0. Intratracheal infection was done on day 0 according to the following procedure; the front neck skin was cut and opened surgically with scissors, and the tracheal tract was exposed and injected with 40^1 of the bacterial suspension using a micro-glass syringe. After injection, the skin was retouched with an instant adhesive agent (Aron alpha, Toa Gosei, Tokyo). The protective effect of forphenicinol was expressed in terms of the number of mice surviving 14 days after infection.
Determination of Numberof P. aeruginosa No. 12 in MousePeritoneal Cavity The cfu of P. aeruginosa No. 12 in the peritoneal cavity of mice infected intraperitoneally was determined as follows. The mice were bled to death 1, 3, 6 or 24 hours after infection. The bacteria in the peritoneal cavity of each mouse were collected after intraperitoneal injection of 5.0 ml of sterile saline. Serial 10-fold dilutions of peritoneal fluid were plated and cfu counted.
Preparation of Peritoneal Polymorphonuclear Cells (PMN) and Macrophages Peritoneal cells were collected from peritoneal fluid of mice 3 hours after intraperitoneal injection of 2 ml of 0.5% glycogen (Nakarai Chemicals, Ltd., Tokyo). These cells were incubated in a plastic dish for 2 hours, thereafter non-adherent cells were collected and used as PMN.Adherent cells were collected from peritoneal fluid of mice injected intraperitoneally with 1.5 ml of 10 % Proteose peptone (Difco Laboratories, Mich., U.S.A.) 3 days before sacrifice by excluding non-adherent cells and used as macrophages.
Bactericidal Activity of PMNand Macrophages PMNor macrophages were suspended with P. aeruginosa No. 12 (cell ratio, 4 : 1 to 8 : 1) in Eagle's minimum essential medium (MEM)containing 5 %ICR mouse serum in a CO2-incubator for 2 hours. The number of remaining viable bacteria was determined as described above.
Determination of Lysozyme and Superoxide Anion in PMN Lysozymeactivity released in the culture mediumof PMNwas measuredaccording to the method of Litwack6). Egg white lysozyme (Seikagaku-Kogyo, Tokyo) and heat killed Micrococcus lysodeikticus (Seikagaku-Kogyo, Tokyo) were used as standard enzyme and substrate. Aliquots of 150 [A of 0.75 mg/ml substrate suspension was incubated with 100 [A of PMN-cultured supernatant at 37°C for 3 hours and the turbidity of the reaction mixture was measured at 540 nm. Superoxide anion production by PMNwas measured by the nitroblue tetrazolium (NBT, Sigma, U.S.A.) reduction method described by Baehner and Nathan7). The concentration of superoxide dismutase (Sigma, U.S.A.) and phorbol myristate acetate (Sigma, U.S.A.) employed was 0.1 mg/ml and 0.5 jwg/ml, respectively.
Statistics
The statistical significances of the survival periods were determined by F-test according to Nakamura and Kimura8) and Chi-square-test.
The other data were analyzed by Student's t-test. A P-value of lower than 0.05 was considered to be significant.
Results
Effect of Forphenicinol on P. aeruginosa Infection in Normal
and ImmunodepressedMice LD50value of intravenous, intraperitoneal or intratracheal infection with P. aeruginosa No. 12 in normal mice was 2.0xlO8, 9.0xlO7 or 2.0x107cfu/mouse, respectively.
Mice were the most sensitive to intratracheal infection. Cyclophosphamide reduced host resistance dose-dependently; an especially large reduction was observed in mice infected intratracheally.
LD50 values in cyclophosphamide (100 mg/kg)-treated mice were 6.0 x lO7 (intravenous), 2.3 x lO7 (intraperitoneal) and 2.5 x 105 (intratracheal) cfu/mouse. In addition, an LD50 value of mice treated with cyclophosphamide (200 mg/kg) was also reduced to 4.0 x 104 cfu/mouse in intratracheal infection. As shown in Table 1 , forphenicinol (0.5 mg/kg) increased the survival rate of ICR mice infected with P. aeruginosa strain No. 12 intravenously and intratracheally at varied administration schedules.
In case of the intratracheal infection, the survival rate of mice given forphenicinol 1 day before the infection went up to 85.7 from 21.4%. Appropriate administration day(s) appeared to be just around the infection. The protective effect of forphenicinol was observed at doses of 0.1 and 0.5 mg/kg when it was given 1 day before intratracheal infection (3.0 x 107 cfu, Table 2 ). This effective dose range was almost the same as that showing activity in the immuneresponses and antitumor effects1"50. O cfu of bacteria in the peritoneal cavity of control mice. ® cfu of bacteria in the peritoneal cavity of mice treated with FPL. * P<0.05 against control mice by Student's t-test. Effect of Forphenicinol on the Growth of P. aeruginosa in Peritoneal Cavity As shown in Fig. 1 , oral administration of forphenicinol (0.5 mg/kg) 1 day before intraperitoneal infection with 5.0 x lO7 cfu/mouse of P. aeruginosa No. 12 decreased the number of bacteria. The number of P. aeruginosa No. 12 in the peritoneal cavity of mice given forphenicinol was 0.8 x 104 cfu 3 hours after and 5.0x 103 cfu 24 hours after infection. It was 47.1 and 5.6% of the control, respectively.
Killing Effect of PMNand Macrophages Taken from Mice Treated with Forphenicinol on P. aeruginosa PMNwere incubated with 1.7x105 cfu/ml of P. aeruginosa No. 12 at a ratio of 8 : 1 for 2 hours at 37°C. Bacteria alone grew up to 1.2xlO6 cfu/ml (Fig. 2) . Oral administration of forphenicinol 1 day before sacrifice enhanced the killing activity of PMNand reduced the remaining viable bacteria from 2.0x 105 cfu/ml (T/C(%), 16.7%) to 9.6 x 104 cfu/ml (T/C(%), 8.0%). On the other hand, macrophages (cell ratio; 8 : 1) from normal mice also reduced the bacterial growth from 1.5 x 105 cfu/ml to 3.8 x 104 cfu/ml (T/C(%), 25.3 %, P<0.05, by Student's t-test). Oral administration of forphenicinol did not enhance the killing activity of these macrophages. bovine serum for 1 hour. After washing, the cells were added to P. aeruginosa No. 12 suspensions and incubated for 2 hours. Neither the killing activity of PMNnor that of macrophages was enhanced by forphenicinol in vitro.
Stimulation of Bactericidal Activity of PMNby Macrophages PMNwere cultured with macrophages at a ratio of 1:1 in MEMcontaining 10% fetal bovine serum at 37°C for 24 hours in a CO2-incubator. After co-culture, the PMN(1.6 x 106 cells) were added to P. aeruginosa No. 12 (3.O x 105 cfu) in 1 ml of MEMcontaining 5% mouse serum and cultured further for 2 hours. As shown in Fig. 3 , P. aeruginosa No. 12 grew up to 5 .9xl05cfu/ml from 3.0x105cfu/ml in the absence ofPMN. PMNhad a weak bactericidal activity and macrophages taken from normal mice enhanced the bactericidal activity of PMN. b Lysozyme activity of culture fluid of MPhtaken from control mice was 1.36^g/ml. c Lysozyme activity of culture fluid of MPh taken from mice treated with FPL (0.5 mg/kg) 1 day before sacrifice was 2.65^g/ml. d P<0.05, against culture fluid of MPhtaken from control mice by Student's t-test.
The number of P. aeruginosa No. 12 was reduced from 4.6x105 cfu/ml to 3.0x105 cfu/ml. The stimulatory effect of macrophages on the bactericidal activity of PMNwas more marked in those taken from mice given forphenicinol 1 day before sacrifice (1.6 x 10* cfu/ml, P<0.01, PMNcultured with macrophages taken from mice given forphenicinol versus PMNscultured with macrophages taken from normal mice by Student's t-test). Furthermore 24 hour-culture supernatant of macrophages taken from mice treated with forphenicinol 1 day before sacrifice also enhanced the killing activity of PMN.
Effect of Culture Supernatant of Macrophages on Lysozyme
and Superoxide Anion Production of PMN Macrophages (1.0 x lO6 cells/ml) taken from normal or from forphenicinol-treated mice were cultured in serum-free MEMfor 24 hours and the cultured supernatant was collected and pooled. PMN(1.0 x lO6 cells/ml) taken from normal mice were incubated with the pooled supernatant of macrophage culture for 24 hours and were separated to 5 tubes. The supernatant of macrophage culture taken from forphenicinol-treated mice increased the lysozyme and superoxide anion production by PMN, 66.7 and 54.5%, respectively (Table 5) . Moreover, PMNwere activated by the cultured supernatant of macrophages incubated with forphenicinol for 24 hours in vitro. The superoxide anion of PMNwas increased by 36.4% (P<0.05, by Student's t-test). Whereas the cultured supernatant of macrophage taken from normal mice did not enhance them. Activity of the supernatant of macrophage culture was not affected by treatment with heating (56°C, 30 minutes) or with acid (pH2.0).
Discussion
Forphenicinol which has low toxicity2) is a low molecular weight immunomodifier. Westudied the protective effect of forphenicinol against P. aeruginosa infection and the mechanisms of action.
P. aeruginosa has been suggested to be a major pathogen in chronic respiratory infections in immunodepressed patients9»10), who are infected with bacteria easily and repeatedly10. The depression in delayed-type hypersensitivity after infection with P. aeruginosa has been reported12>13). Moreover, it is well known that the efficacy of chemotherapy is reduced in immunodepressed patients. In this case, both macrophages and PMNcan play an important role in the host defense mechanisms14). Ishizuka et alP have reported that forphenicinol restores delayed-type hypersensitivity in immunodepressed mice and enhances the activity of peritoneal macrophages. In the present study, we found that the protective effect of forphenicinol against P. aeruginosa was associated with the increase in killing activity of PMNthrough macrophage activation in vivo, because PMNwere activated by APR. 1987 macrophages taken from mice treated with forphenicinol and by cultured supernatant of macrophages incubated with forphenicinol in vitro, but not by forphenicinol directly. As has been reported previously, forphenicinol enhances the production of f-interferon and tumor necrosis factor by macrophages15>16). As reported in this study we found that forphenicinol stimulates macrophages to produce a heat-and acid-stable factor which activates PMNto inhibit the growth of P. aeruginosa. It is knownthat interleukin 1 is a major product of macrophages and responsible for inflamation. Therefore, we are going to examine whether interleukin 1 enhances PMNor not. While, Pennington et ah have reported that humanalveolar macrophagesproduce a PMN-activating factor17).
